(Q54500784)

30 May 2018

title

Comparison of visual and automated assessment of HER2 status and their impact on outcome in primary operable invasive ductal breast cancer. (English)

1 reference

30 May 2018

0 references

2

1 reference

30 May 2018

Joanne Edwards

7

1 reference

30 May 2018

Donald C McMillan

object named as

Donald C McMillan

3

0 references

author name string

Zahra M A Mohammed

1

1 reference

30 May 2018

Clare Orange

4

1 reference

30 May 2018

Elizabeth Mallon

5

1 reference

30 May 2018

Julie C Doughty

6

1 reference

30 May 2018

publication date

1 October 2012

1 reference

30 May 2018

published in

Histopathology

1 reference

30 May 2018

volume

61

1 reference

30 May 2018

issue

4

1 reference

30 May 2018

page(s)

675-684

1 reference

30 May 2018

Estimating the world cancer burden: Globocan 2000.

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2012.04280.X

Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2012.04280.X

HER2 testing: a review of detection methodologies and their clinical performance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2012.04280.X

Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2012.04280.X

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2012.04280.X

Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2012.04280.X

HER-2 and topoisomerase II as predictors of response to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2012.04280.X

Outcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2012.04280.X

High inter-observer agreement in immunohistochemical evaluation of HER-2/neu expression in breast cancer: a multicentre GEFPICS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2012.04280.X

Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2012.04280.X

Analytical validation and interobserver reproducibility of EnzMet GenePro: a second-generation bright-field metallography assay for concomitant detection of HER2 gene status and protein expression in invasive carcinoma of the breast.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2012.04280.X

HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2012.04280.X

Image analysis as an adjunct to manual HER-2 immunohistochemical review: a diagnostic tool to standardize interpretation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2012.04280.X

Time course of chromatic adaptation for color appearance and discrimination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2012.04280.X

Assessment of automated image analysis of breast cancer tissue microarrays for epidemiologic studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2012.04280.X

Semi-automated imaging system to quantitate Her-2/neu membrane receptor immunoreactivity in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2012.04280.X

Study on breast carcinoma Her2/neu and hormonal receptors status assessed by automated images analysis systems: ACIS III (Dako) and ScanScope (Aperio).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2012.04280.X

Inter-observer reproducibility of HER2 immunohistochemical assessment and concordance with fluorescent in situ hybridization (FISH): pathologist assessment compared to quantitative image analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2012.04280.X

Tissue microarrays for high-throughput molecular profiling of tumor specimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2012.04280.X

The Measurement of Observer Agreement for Categorical Data

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2012.04280.X

Automated image analysis for high-throughput quantitative detection of ER and PR expression levels in large-scale clinical studies: the TEAM Trial Experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2012.04280.X

Development and evaluation of a virtual microscopy application for automated assessment of Ki-67 expression in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2012.04280.X

Evaluation of oestrogen and progesterone receptor status in HER-2 positive breast carcinomas and correlation with outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2559.2012.04280.X

10.1111/J.1365-2559.2012.04280.X

21 January 2018

Identifiers

DOI

1 reference

30 May 2018

1 reference

30 May 2018